Rhythm Pharmaceuticals, Inc.NASDAQ: RYTM

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

· Issued by Rhythm Pharmaceuticals, Inc.
Watch Rhythm Pharmaceuticals explain itRhythm Pharmaceuticals, Inc. (RYTM) Q2 2026 Earnings Call · Replay · Aug 4

-- Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks (p